APOE genotype and survival in men and women with Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The epsilon 4 allele of the APOE gene (APOE) is more frequent in patients with AD than in the general population, but studies are inconclusive as to whether it affects rate of progression or survival. Because survival in AD is generally longer in women than in men, the authors investigated whether APOE affects 10-year survival equally in men and women. METHODS: APOE testing was performed on 125 patients with probable AD enrolled in the Johns Hopkins AD Research Center between November 1984 and March 1987. The 39 men and 86 women were followed at 6-month intervals until censoring (by death or withdrawal from the study) or March 1997. Patients were dichotomized into those with and those without at least one epsilon 4 allele. For each sex, a Cox proportional hazards regression, allowing for delayed entry and covarying for age at onset, was used to examine the effect of epsilon 4 on survival. RESULTS: All patients who died during the study period and had autopsy (n = 92) were found to have definite AD. Average survival from disease onset did not differ by sex (12.1 years in men; 12.3 years in women). In neither sex were differences found between epsilon 4-positive and epsilon 4-negative subgroups in education, duration of AD at entry, or severity of dementia. However, in both sexes the epsilon 4-positive subgroup was approximately 3 years older at onset of AD and at entry to the study than the epsilon 4-negative subgroup. Adjusting for age at onset, the presence of an epsilon 4 allele significantly increased the relative risk of death only for men (RR = 2.69; 95% CI = 1.23 to 5.87). CONCLUSIONS: In this sample of mostly white, well-educated research participants with AD, the APOE epsilon 4 allele was associated with shorter survival in men but not in women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R., Knoefel, J. E., CobbS, J., Belanger, A., D'Agostino, R. B., & White, L. R. (1992) · Neurology · doi:10.1212/wnl.42.1.115 · Cited by 527
Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R. T., Knoefel, J. E., Cobb, J. L., Belanger, A. J., White, L. R., & D'Agostino, R. B. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.515 · Cited by 470
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
Lautenschlager, N. T., Cupples, L. A., Rao, V. S., Auerbach, S. A., Becker, R., Burke, J., Chui, H., Duara, R., Foley, E. J., Glatt, S. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.641 · Cited by 298
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
Frisoni, G. B., Govoni, S., Geroldi, C., Bianchetti, A., Calabresi, L., Franceschini, G., & Trabucchi, M. (1995) · Annals of Neurology · doi:10.1002/ana.410370509 · Cited by 149
Cited by
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
Mediterranean diet and Alzheimer disease mortality
Scarmeas, N., Luchsinger, J. A., Mayeux, R., & Stern, Y. (2007) · Neurology · doi:10.1212/01.wnl.0000277320.50685.7c · Cited by 326
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
“Several studies have suggested that patients with APOE4 have a shorter survival after diagnosis than their APOE3 counterparts (Dal Forno et al. 2002; Tilvis et al. 1998).”
APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease
Cosentino, S., Scarmeas, N., Helzner, E., Glymour, M. M., Brandt, J., Albert, M., Blacker, D., & Stern, Y. (2008) · Neurology · doi:10.1212/01.wnl.0000304038.37421.cc · Cited by 214
Self-citation
Metadata
- Authors
- Dal Forno, G., Carson, K. A., Brookmeyer, R., Troncoso, J., Kawas, C. H., & Brandt, J.
- Venue
- Neurology
- Published
- 2002-04-09
- Volume
- 58
- Issue
- 7
- Pages
- 1045-1050
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2075325038
- Cited by
- 62
- References
- 8
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APOE genotype and survival in men and women with Alzheimer’s disease. https://app.cochat.ai/papers/10.1212/wnl.58.7.1045
- The paper
- Dal Forno, G., Carson, K. A., Brookmeyer, R., Troncoso, J., Kawas, C. H., & Brandt, J. (2002). APOE genotype and survival in men and women with Alzheimer’s disease. Neurology. https://doi.org/10.1212/wnl.58.7.1045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.